JP2021503449A - 眼障害の処置のための組成物及び方法 - Google Patents
眼障害の処置のための組成物及び方法 Download PDFInfo
- Publication number
- JP2021503449A JP2021503449A JP2020526481A JP2020526481A JP2021503449A JP 2021503449 A JP2021503449 A JP 2021503449A JP 2020526481 A JP2020526481 A JP 2020526481A JP 2020526481 A JP2020526481 A JP 2020526481A JP 2021503449 A JP2021503449 A JP 2021503449A
- Authority
- JP
- Japan
- Prior art keywords
- administration
- formula
- compound
- eye
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- AGBQKNBQESQNJD-UHFFFAOYSA-N OC(CCCCC1SSCC1)=O Chemical compound OC(CCCCC1SSCC1)=O AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- ZSTQLVWMDWJSGT-UHFFFAOYSA-O CC(C1OC1OC1)C1C=CCC1=CN=C[NH+]1C Chemical compound CC(C1OC1OC1)C1C=CCC1=CN=C[NH+]1C ZSTQLVWMDWJSGT-UHFFFAOYSA-O 0.000 description 1
- 0 CC=CC[C@@]([C@@](*c1cnc[n]1C)CO1)C1=O Chemical compound CC=CC[C@@]([C@@](*c1cnc[n]1C)CO1)C1=O 0.000 description 1
- GCZMAXUTTKMOOD-ZOHDFZEYSA-N C[C@@H](C(COC1)=C=CC#Cc2cnc[n]2C)C1=O Chemical compound C[C@@H](C(COC1)=C=CC#Cc2cnc[n]2C)C1=O GCZMAXUTTKMOOD-ZOHDFZEYSA-N 0.000 description 1
- GKXZAKTXYUPZPE-IUCAKERBSA-N C[C@@H]([C@H](C=[O]1)C#Cc2cnc[n]2C)C1=O Chemical compound C[C@@H]([C@H](C=[O]1)C#Cc2cnc[n]2C)C1=O GKXZAKTXYUPZPE-IUCAKERBSA-N 0.000 description 1
- IPDBFHHCXGUAKV-UHFFFAOYSA-N OC(CCCCC1SSCC1)O Chemical compound OC(CCCCC1SSCC1)O IPDBFHHCXGUAKV-UHFFFAOYSA-N 0.000 description 1
- AGBQKNBQESQNJD-ZETCQYMHSA-N OC(CCCC[C@@H]1SSCC1)=O Chemical compound OC(CCCC[C@@H]1SSCC1)=O AGBQKNBQESQNJD-ZETCQYMHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本出願は、2017年11月17日出願のインド仮特許出願第201741041231号の利益を主張するものであり、その内容全体が引用することにより本明細書の一部をなす。
溶媒中のピロカルピン塩を一定期間、塩基で処理して、ピロカルピンの遊離塩基を得ることができ、この遊離塩基とリポ酸とを接触させることで、式Iの化合物の形成が起こる。代替的には、ピロカルピンとリポ酸とを接触させて、式Iの化合物を直接得ることができる。当業者であれば、最適な溶媒、塩基、及び温度、時間等のようなプロセスパラメータを適切に修正/選択し、その意図する目的を達成することができるが、本開示の範囲は、任意の特定の溶媒/塩基及び/又はプロセスパラメータの利用に限らないことを理解するであろう。
本開示は、特に神経疾患及びその合併症を処置するための組成物及び方法を提供する。本開示の特定の実施形態について詳述したが、上記の明細書は例示的なものであり、制限するものではない。本明細書の系及び方法の多くの変形例について、本明細書を検討すれば当業者には明らかとなるであろう。特許請求した系及び方法の全範囲は、特許請求の範囲とその等価物の全範囲、及び明細書とそのような変形例を参照して決定するものとする。
上記に挙げたものを含む本明細書で言及した全ての刊行物及び特許は、各々の刊行物又は特許が詳細にかつ個々に参照により引用されると示されているかのように、その内容全体を引用することにより本明細書の一部をなす。矛盾する場合、本明細書における任意の定義を含む本出願に従うものとする。
段階1:アセトン中のピロカルピンHClを、室温で18時間、炭酸水素ナトリウムで処理し、ピロカルピンの遊離塩基を得て、この遊離塩基と(R)−リポ酸とを室温で1時間、反応させることで、約100%の収率でピロカルピン−(R)−リポ酸塩[5−(((3R,4S)−4−エチル−5−オキソテトラヒドロフラン−3−イル)メチル)−1−メチル−1H−イミダゾール−1−イウム(R)−5−(1,2−ジチオラン−3−イル)ペンタノエート]を得た。
DMSO−d6溶媒中のピロカルピン−(R)−リポ酸塩の1H−NMRを得て、対応するプロトンのケミカルシフト値を下記の表1に与える。
薬物動態研究を雄性のニュージーランド白ウサギにて行い、CLX−156(ピロカルピン−(R)−リポ酸塩)配合物の眼の薬物動態を評価した。動物の各眼に50μLのCLX−156を局所投与し、房水及び血液試料を採取した後、動物を屠殺して所与の時点で水晶体、角膜及び虹彩領域を採取した。
Claims (18)
- 前記眼障害が、黄斑変性、白内障、緑内障、糖尿病性網膜症、ドライアイ、眼神経炎、網膜色素変性症、及び老視からなる群より選択される、請求項1に記載の化合物。
- 眼障害又はその合併症を処置するための医薬組成物であって、少なくとも1つの請求項1又は2に記載の化合物と、薬学的に許容可能な添加剤とを含む、医薬組成物。
- 経口投与、鼻腔投与、局所投与、直腸投与、膣内投与、エアロゾル投与、又は非経口投与のために配合されている、請求項4に記載の医薬組成物。
- 局所眼科用配合物である、請求項4に記載の医薬組成物。
- 点眼配合物である、請求項4に記載の医薬組成物。
- 請求項1に記載の化合物を合成する方法であって、ピロカルピンをリポ酸で処理することを含む、方法。
- 前記投与が、前記式Iの化合物の経口投与、鼻腔投与、局所投与、直腸投与、膣内投与、エアロゾル投与又は非経口投与を含む、請求項9に記載の方法。
- 前記式Iの化合物を薬学的に許容可能な添加剤とともに前記被験体に投与する、請求項9に記載の方法。
- 前記式Iの化合物を点眼剤、スワブ、軟膏、ジェル、又はミストの形態で局所投与する、請求項9に記載の方法。
- 前記式Iの化合物を前記被験体の少なくとも一方の眼に局所投与する、請求項9に記載の方法。
- 前記治療有効量が0.001mg〜1000mgの範囲である、請求項9に記載の方法。
- 前記被験体がヒトである、請求項9に記載の方法。
- 前記眼障害が、黄斑変性、白内障、緑内障、糖尿病性網膜症、ドライアイ、眼神経炎、網膜色素変性症、及び老視からなる群より選択される、請求項9に記載の方法。
- 眼障害又はそれに関連する合併症を処置する医薬の製造のための請求項1又は2に記載の化合物の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201741041231 | 2017-11-17 | ||
IN201741041231 | 2017-11-17 | ||
PCT/IB2018/057342 WO2019097318A1 (en) | 2017-11-17 | 2018-09-22 | Compositions and methods for the treatment of eye disorders |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2021503449A true JP2021503449A (ja) | 2021-02-12 |
JP2021503449A5 JP2021503449A5 (ja) | 2021-05-13 |
JP7006990B2 JP7006990B2 (ja) | 2022-02-10 |
Family
ID=66540065
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020526481A Active JP7006990B2 (ja) | 2017-11-17 | 2018-09-22 | 眼障害の処置のための組成物及び方法 |
Country Status (14)
Country | Link |
---|---|
US (1) | US10933052B2 (ja) |
EP (1) | EP3651747A4 (ja) |
JP (1) | JP7006990B2 (ja) |
KR (1) | KR102349776B1 (ja) |
CN (1) | CN111372576A (ja) |
AU (1) | AU2018367909B2 (ja) |
BR (1) | BR112020009361A2 (ja) |
CA (1) | CA3081553C (ja) |
IL (1) | IL274234B2 (ja) |
MX (1) | MX2020004666A (ja) |
RU (1) | RU2761436C1 (ja) |
SG (1) | SG11202004019SA (ja) |
WO (1) | WO2019097318A1 (ja) |
ZA (1) | ZA202002066B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021512876A (ja) * | 2018-02-05 | 2021-05-20 | セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited | 抗ムスカリン薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2749189C2 (ru) * | 2016-10-04 | 2021-06-07 | Целликс Био Прайвет Лимитед | Композиции и способы лечения ксеростомии |
NZ763699A (en) * | 2017-11-17 | 2022-05-27 | Cellix Bio Private Ltd | Compounds, compositions and methods for treatment of eye disorders and skin diseases |
MX2022006803A (es) * | 2019-12-04 | 2022-09-19 | Restore Vision Llc | Formulaciones oftalmicas para el tratamiento de la presbicia. |
TWI819268B (zh) * | 2020-01-16 | 2023-10-21 | 詹姆斯 W 希爾 | 藉由基因轉導改變眼睛顏色 |
AU2021278406A1 (en) * | 2020-05-26 | 2022-12-08 | Cellix Bio Private Limited | Pharmaceutical formulations of pilocarpine R-(+)-lipoate |
WO2023052974A1 (en) * | 2021-09-29 | 2023-04-06 | Avaca Pharma Private Limited | Ocular compositions and methods for the treatment of ophthalmic diseases and disorders |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004537522A (ja) * | 2001-06-07 | 2004-12-16 | マリー−テレーズ ドロワ−ルフェ | 眼表面異常の治療及び/又は予防薬の製造における抗酸化剤の使用 |
US20090156606A1 (en) * | 2007-12-15 | 2009-06-18 | Anant Sharma | Optical correction |
JP2009541220A (ja) * | 2006-06-16 | 2009-11-26 | インディジーン ファーマシューティカルズ インコーポレイテッド | 糖尿病性高血糖および糖尿病合併症の制御のための抗糖尿病薬としてのメトホルミンr−(+)リポエート |
WO2010125416A1 (en) * | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
US20140221467A1 (en) * | 2013-02-07 | 2014-08-07 | Banavara L. Mylari | Metformin derivatives for treating diabetes and diabetes complications |
CN104387364A (zh) * | 2014-12-15 | 2015-03-04 | 南京工业大学 | L-鸟氨酸硫辛酸复合盐及其制备方法和应用 |
WO2015103577A1 (en) * | 2014-01-06 | 2015-07-09 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating dominant optic atrophy |
JP2016508140A (ja) * | 2012-12-28 | 2016-03-17 | チョン クン ダン ファーマシューティカル コーポレーション | カチオン性薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬剤学的組成物 |
JP2019531302A (ja) * | 2016-10-04 | 2019-10-31 | セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited | 口内乾燥症(xerostomia)の治療のための組成物および方法 |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL50250A (en) | 1975-08-27 | 1980-01-31 | Hydrophilics Int Inc | Sustained release compositions comprising slats of pharmaceutically acitve bases with polymers containing acid groups |
US4076942A (en) | 1975-10-01 | 1978-02-28 | Merck & Co., Inc. | Crystalline dipilocarpinium pamoate |
FR2424930A1 (fr) | 1978-05-02 | 1979-11-30 | Inst Khim Drevesiny Akadem | Nouveaux polymeres d'alcoyl-1(oxo-5 alcoyl-4 tetrahydrofuryl-methyl(3)-5) imidazoles et d'ethers carboxyalcoyliques d'alcool polyvinylique, utiles notamment comme agents m-cholinomimetiques et leur procede de preparation |
US4977176A (en) | 1987-01-31 | 1990-12-11 | Sandoz Ltd. | Pilocarpine compounds which are used as pharmaceutical agents |
NL8800099A (nl) | 1987-01-31 | 1988-08-16 | Sandoz Ag | Pilocarpinederivaten en werkwijzen voor het bereiden en toepassen van deze derivaten. |
US5080646A (en) | 1988-10-03 | 1992-01-14 | Alza Corporation | Membrane for electrotransport transdermal drug delivery |
JP2771257B2 (ja) | 1989-06-22 | 1998-07-02 | 岩城製薬株式会社 | イミダゾール誘導体の製法 |
US5322942A (en) | 1991-06-03 | 1994-06-21 | Regents Of The University Of California | Synthesis of optically active lactones from L-aspartic acid and intermediates thereof |
DE4222459C2 (de) | 1992-07-08 | 1995-09-14 | Sigma Tau Ind Farmaceuti | 3,9-disubstituierte-Spiro[5.5]undecane, ein Verfahren zu deren Herstellung und pharmazeutische Zusammensetzungen, die diese enthalten |
IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
US5783701A (en) | 1992-09-08 | 1998-07-21 | Vertex Pharmaceuticals, Incorporated | Sulfonamide inhibitors of aspartyl protease |
US5723490A (en) | 1992-09-08 | 1998-03-03 | Vertex Pharmaceuticals Incorporated | THF-containing sulfonamide inhibitors of aspartyl protease |
DE4334135A1 (de) | 1993-10-07 | 1995-04-13 | Merck Patent Gmbh | Verfahren zur Herstellung von Pilocarpin-Derivaten |
IL113459A (en) | 1995-04-23 | 2000-07-16 | Electromagnetic Bracing System | Electrophoretic cuff apparatus |
CA2230894A1 (en) | 1995-09-01 | 1997-03-13 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
US5811428A (en) | 1995-12-18 | 1998-09-22 | Signal Pharmaceuticals, Inc. | Pyrimidine carboxamides and related compounds and methods for treating inflammatory conditions |
US6239180B1 (en) | 1995-11-08 | 2001-05-29 | The Regents Of The University Of California | Transdermal therapeutic device and method with capsaicin and capsaicin analogs |
ES2171878T3 (es) | 1996-01-22 | 2002-09-16 | Fujisawa Pharmaceutical Co | Derivados de tiazolilbenzofurano y composiciones farmaceuticas que los contienen. |
ATE387192T1 (de) | 1997-10-28 | 2008-03-15 | Bando Chemical Ind | Dermatologisches pflaster und verfahren zur herstellung seiner basisschicht |
US6329369B1 (en) | 1997-12-04 | 2001-12-11 | Allergan Sales, Inc. | Methods of treating pain and other conditions |
US6103275A (en) | 1998-06-10 | 2000-08-15 | Nitric Oxide Solutions | Systems and methods for topical treatment with nitric oxide |
DE19827732A1 (de) | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
US6222039B1 (en) | 1998-07-13 | 2001-04-24 | Hoffman-La Roche Inc. | Process for the preparation of chiral lactones |
US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
US6312716B1 (en) | 1999-05-10 | 2001-11-06 | Peierce Management Llc | Patch and method for transdermal delivery of bupropion base |
TWI283669B (en) | 1999-06-10 | 2007-07-11 | Allergan Inc | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors |
US6974588B1 (en) | 1999-12-07 | 2005-12-13 | Elan Pharma International Limited | Transdermal patch for delivering volatile liquid drugs |
US7098209B2 (en) | 2001-06-05 | 2006-08-29 | Lilly Icos Llc | Pyrazino [1'2':1,6 ] pyrido [3, 4-b] indole-1,4-dione derivatives |
RU2352568C9 (ru) | 2002-08-09 | 2009-06-27 | Астразенека Аб | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 |
US20060241082A1 (en) | 2002-09-19 | 2006-10-26 | Fleckenstein Annette E | Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson's disease |
GB0309850D0 (en) | 2003-04-30 | 2003-06-04 | Astrazeneca Ab | Quinazoline derivatives |
DE10358539A1 (de) | 2003-12-15 | 2005-07-07 | Merck Patent Gmbh | Carbonsäureamidderivate |
DK1737461T3 (da) | 2004-03-15 | 2013-03-18 | Ptc Therapeutics Inc | Carbolin-derivater til inhibering af angiogenese |
US8076352B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Administration of carboline derivatives useful in the treatment of cancer and other diseases |
US7767689B2 (en) | 2004-03-15 | 2010-08-03 | Ptc Therapeutics, Inc. | Carboline derivatives useful in the treatment of cancer |
US8076353B2 (en) | 2004-03-15 | 2011-12-13 | Ptc Therapeutics, Inc. | Inhibition of VEGF translation |
EP1849781A1 (en) | 2006-04-28 | 2007-10-31 | Laboratorios del Dr. Esteve S.A. | Substituted 3-Amino-4-hydroxy pyrrolidines compounds, their preparation and use as medicaments |
BRPI0714409A2 (pt) | 2006-07-14 | 2013-03-12 | Novartis Ag | derivados de pirimidina como inibidores de alk-5 |
PL2231642T3 (pl) | 2008-01-11 | 2014-04-30 | Novartis Ag | Pirymidyny jako inhibitory kinazy |
WO2009105782A1 (en) | 2008-02-21 | 2009-08-27 | Sequoia Pharmaceuticals, Inc. | Hiv protease inhibitor and cytochrome p450 inhibitor combinations |
US20090326004A1 (en) | 2008-06-03 | 2009-12-31 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
JP2011528341A (ja) | 2008-07-18 | 2011-11-17 | 武田薬品工業株式会社 | ベンズアゼピン誘導体及びそれらのヒスタミンh3拮抗薬としての使用 |
US20110091459A1 (en) | 2008-12-11 | 2011-04-21 | Auspex Pharmaceuticals, Inc. | Imidazole modulators of muscarinic acetylcholine receptor m3 |
EP3318264A1 (en) * | 2009-08-24 | 2018-05-09 | Stealth Peptides International, Inc. | Methods ans compositions for preventing or treating opthalmic conditions |
WO2011113060A2 (en) | 2010-03-12 | 2011-09-15 | Trana Discovery, Inc. | Antiviral compounds and methods of use thereof |
GB201007187D0 (en) | 2010-04-29 | 2010-06-09 | Iti Scotland Ltd | Ubiquitination modulators |
ES2634087T3 (es) | 2010-06-03 | 2017-09-26 | Alnylam Pharmaceuticals, Inc. | Lípidos biodegradables para la administración de agentes activos |
MY162132A (en) | 2010-06-23 | 2017-05-31 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
CN102432598A (zh) | 2010-09-29 | 2012-05-02 | 江苏恒瑞医药股份有限公司 | 三环化合物、其制备方法及其在医药上的应用 |
WO2012065057A2 (en) | 2010-11-12 | 2012-05-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
BR112013013457A2 (pt) | 2010-11-30 | 2017-07-11 | Genentech Inc | métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composições |
WO2012079032A2 (en) | 2010-12-09 | 2012-06-14 | Trana Discovery, Inc. | Compositions and methods of treating drug-resistant retroviral infections |
ES2571741T3 (es) | 2011-03-31 | 2016-05-26 | Bayer Ip Gmbh | Bencimidazoles sustituidos como inhibidores de Mps-1 quinasa |
CA2832310A1 (en) | 2011-04-06 | 2012-10-11 | Bayer Intellectual Property Gmbh | Substituted imidazopyridines and intermediates thereof |
JP2012230356A (ja) | 2011-04-15 | 2012-11-22 | Sumitomo Chemical Co Ltd | 化合物、レジスト組成物及びレジストパターンの製造方法 |
GB201114448D0 (en) | 2011-08-22 | 2011-10-05 | Takeda Pharmaceutical | Compounds and their use |
US20140228384A1 (en) | 2011-11-29 | 2014-08-14 | Genentech, Inc. | Assays and biomarkers for lrrk2 |
GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
CN104080773B (zh) | 2012-01-28 | 2016-12-28 | 默克专利股份公司 | 氮杂环化合物 |
WO2013144191A1 (de) | 2012-03-29 | 2013-10-03 | Bayer Intellectual Property Gmbh | Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen |
JP6449880B2 (ja) | 2013-08-08 | 2019-01-09 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規ピラジンアミド化合物 |
EP3077003A1 (en) | 2013-12-03 | 2016-10-12 | Bayer Pharma Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2015082376A2 (en) | 2013-12-03 | 2015-06-11 | Bayer Pharma Aktiengesellschaft | Use of pi3k-inhibitors |
US9458156B2 (en) | 2014-12-23 | 2016-10-04 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
CR20170017A (es) | 2014-07-01 | 2017-05-16 | Takeda Pharmaceuticals Co | Compuesto heterocíclico |
-
2018
- 2018-09-22 EP EP18879678.3A patent/EP3651747A4/en not_active Withdrawn
- 2018-09-22 CN CN201880071277.XA patent/CN111372576A/zh active Pending
- 2018-09-22 KR KR1020207017159A patent/KR102349776B1/ko active IP Right Grant
- 2018-09-22 AU AU2018367909A patent/AU2018367909B2/en active Active
- 2018-09-22 MX MX2020004666A patent/MX2020004666A/es unknown
- 2018-09-22 WO PCT/IB2018/057342 patent/WO2019097318A1/en unknown
- 2018-09-22 SG SG11202004019SA patent/SG11202004019SA/en unknown
- 2018-09-22 BR BR112020009361-0A patent/BR112020009361A2/pt active Search and Examination
- 2018-09-22 JP JP2020526481A patent/JP7006990B2/ja active Active
- 2018-09-22 CA CA3081553A patent/CA3081553C/en active Active
- 2018-09-22 RU RU2020119218A patent/RU2761436C1/ru active
-
2020
- 2020-02-13 US US16/790,492 patent/US10933052B2/en active Active
- 2020-04-26 IL IL274234A patent/IL274234B2/en unknown
- 2020-05-04 ZA ZA2020/02066A patent/ZA202002066B/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004537522A (ja) * | 2001-06-07 | 2004-12-16 | マリー−テレーズ ドロワ−ルフェ | 眼表面異常の治療及び/又は予防薬の製造における抗酸化剤の使用 |
JP2009541220A (ja) * | 2006-06-16 | 2009-11-26 | インディジーン ファーマシューティカルズ インコーポレイテッド | 糖尿病性高血糖および糖尿病合併症の制御のための抗糖尿病薬としてのメトホルミンr−(+)リポエート |
US20090156606A1 (en) * | 2007-12-15 | 2009-06-18 | Anant Sharma | Optical correction |
WO2010125416A1 (en) * | 2009-04-27 | 2010-11-04 | Raouf Rekik | Drug delivery to the anterior and posterior segments of the eye |
JP2016508140A (ja) * | 2012-12-28 | 2016-03-17 | チョン クン ダン ファーマシューティカル コーポレーション | カチオン性薬理学的活性物質の徐放性脂質初期製剤およびこれを含む薬剤学的組成物 |
US20140221467A1 (en) * | 2013-02-07 | 2014-08-07 | Banavara L. Mylari | Metformin derivatives for treating diabetes and diabetes complications |
WO2015103577A1 (en) * | 2014-01-06 | 2015-07-09 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating dominant optic atrophy |
CN104387364A (zh) * | 2014-12-15 | 2015-03-04 | 南京工业大学 | L-鸟氨酸硫辛酸复合盐及其制备方法和应用 |
JP2019531302A (ja) * | 2016-10-04 | 2019-10-31 | セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited | 口内乾燥症(xerostomia)の治療のための組成物および方法 |
Non-Patent Citations (2)
Title |
---|
FREITAS, R. M.: "The evaluation of effects of lipoic acid on the lipid peroxidation, nitrite formation and antioxidan", NEUROSCIENCE LETTERS, vol. 455, JPN6021021655, 2009, pages 140 - 144, XP026066903, ISSN: 0004609508, DOI: 10.1016/j.neulet.2009.03.065 * |
MENDES DE FREITAS, RIVELILSON: "Lipoic Acid Increases Hippocampal Choline Acetyltransferase and Acetylcholinesterase Activities and", NEUROCHEM RES, vol. 35, JPN6021021658, 2010, pages 162 - 170, ISSN: 0004609507 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021512876A (ja) * | 2018-02-05 | 2021-05-20 | セリックス バイオ プライヴェート リミテッドCellix Bio Private Limited | 抗ムスカリン薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用 |
Also Published As
Publication number | Publication date |
---|---|
MX2020004666A (es) | 2022-01-26 |
EP3651747A1 (en) | 2020-05-20 |
CA3081553A1 (en) | 2019-05-23 |
CA3081553C (en) | 2022-11-15 |
IL274234A (en) | 2020-06-30 |
US10933052B2 (en) | 2021-03-02 |
WO2019097318A1 (en) | 2019-05-23 |
IL274234B2 (en) | 2023-02-01 |
AU2018367909A1 (en) | 2020-05-07 |
BR112020009361A2 (pt) | 2020-10-13 |
SG11202004019SA (en) | 2020-05-28 |
JP7006990B2 (ja) | 2022-02-10 |
EP3651747A4 (en) | 2020-07-22 |
ZA202002066B (en) | 2021-07-28 |
IL274234B (en) | 2022-10-01 |
RU2761436C1 (ru) | 2021-12-08 |
CN111372576A (zh) | 2020-07-03 |
NZ763688A (en) | 2021-10-29 |
US20200179343A1 (en) | 2020-06-11 |
KR20200089292A (ko) | 2020-07-24 |
AU2018367909B2 (en) | 2022-03-10 |
KR102349776B1 (ko) | 2022-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7006990B2 (ja) | 眼障害の処置のための組成物及び方法 | |
CA2819628C (en) | Folic acid - ramipril combination: cellprotective, neuroprotective and retinoprotective ophtalmologic compositions | |
JP7038437B2 (ja) | 眼障害及び皮膚疾患の処置のための化合物、組成物、及び方法 | |
JP6679616B2 (ja) | 炎症及び疼痛の治療のための組成物及び方法 | |
JP2021536439A (ja) | 眼障害及び皮膚疾患の処置のための眼科用組成物及び方法 | |
JP2022516796A (ja) | 選択的αアドレナリン受容体作用薬又は抗コリン作動薬及びリポ酸の組合せ物並びにその使用 | |
JP2022509174A (ja) | 皮膚疾患及び眼疾患の処置のための眼科用組成物及び方法 | |
NZ763688B2 (en) | Compositions and methods for the treatment of eye disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210401 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210401 |
|
A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20210401 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20210416 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210608 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210906 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211005 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211130 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211224 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7006990 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D04 |